Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CND-Dox-TF
- Development stage
- Preclinical
- Lead developer
- University of Miami
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**CND-Dox-TF**, also termed **CDT**, is an investigational transferrin receptor 1-targeted carbon-nitride-dot nanocarrier for delivery of doxorubicin in diffuse large B-cell lymphoma. It consists of carbon-nitride dots covalently conjugated to doxorubicin and human holo-transferrin. The transferrin component binds transferrin receptor 1 on malignant cells and promotes receptor-mediated endocytosis, enabling intracellular release or separation of the doxorubicin-containing component and nuclear accumulation of doxorubicin. In preclinical diffuse large B-cell lymphoma models, CND-Dox-TF produced greater potency than unconjugated doxorubicin, induced DNA damage and apoptosis, and showed improved tolerability when substituted for doxorubicin in R-CHOP-like treatment in patient-derived xenograft models.
- Other names
- CDTcarbon-nitride dot-doxorubicin-transferrin
02
Targets
TFRC (Transferrin Receptor)DNA
Beyond the preview
Go deeper on CND-Dox-TF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CND-Dox-TF.